A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy.

Trial Profile

A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms BioPATH
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 14 Dec 2012 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 10 Aug 2012 Planned end date changed from 1 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top